Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($28.1B)

Data statis (memuat keuangan langsung…)

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

Komposisi segmen dan pelanggan utama

Detail produk

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

Hubungan Rantai Pasok

Pesaing

Pfizer Inc.

Antiviral therapies

Dampak: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

Dampak: Competing in oncology

Mitra

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

Dampak: Research partnership

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Gilead Sciences, Inc..

Info Perusahaan

Kantor Pusat

Foster City, California, USA

Didirikan

1987

Karyawan

18,000+

Situs Web

gilead.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor